Cardiol Therapeutics Company Executives
| CRDL Stock | CAD 3.19 0.12 3.63% |
Cardiol Therapeutics employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Cardiol Therapeutics' management performance can provide insight into the firm performance.
Cardiol |
Cardiol Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4535) % which means that it has lost $0.4535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9211) %, meaning that it generated substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of May 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -1.1. At this time, Cardiol Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 29th of May 2024, Intangible Assets is likely to grow to about 404.7 K, while Total Assets are likely to drop about 38.4 M.As of the 29th of May 2024, Common Stock Shares Outstanding is likely to drop to about 36.6 M. In addition to that, Net Loss is likely to drop to about (29.2 M)
Cardiol Therapeutics Workforce Comparison
Cardiol Therapeutics Class is currently under evaluation in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 115,981. Cardiol Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Cardiol Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cardiol Therapeutics Price Series Summation is a cross summation of Cardiol Therapeutics price series and its benchmark/peer.
Cardiol Therapeutics Notable Stakeholders
A Cardiol Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cardiol Therapeutics often face trade-offs trying to please all of them. Cardiol Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cardiol Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David MBA | CEO President | Profile | |
| Andrew MD | Chief Development | Profile | |
| Trevor Burns | Investor Relations | Profile | |
| Bernard BSc | Chief Officer | Profile | |
| MBA MBA | CEO Pres | Profile | |
| CA CMA | Corp CFO | Profile |
About Cardiol Therapeutics Management Performance
The success or failure of an entity such as Cardiol Therapeutics often depends on how effective the management is. Cardiol Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cardiol management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cardiol management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (0.77) | (0.80) | |
| Return On Equity | (1.00) | (1.05) |
The data published in Cardiol Therapeutics' official financial statements usually reflect Cardiol Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cardiol Therapeutics. For example, before you start analyzing numbers published by Cardiol accountants, it's critical to develop an understanding of what Cardiol Therapeutics' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Cardiol Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cardiol Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cardiol Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cardiol Therapeutics Class. Please utilize our Beneish M Score to check the likelihood of Cardiol Therapeutics' management manipulating its earnings.
Cardiol Therapeutics Workforce Analysis
Traditionally, organizations such as Cardiol Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cardiol Therapeutics within its industry.Cardiol Therapeutics Manpower Efficiency
Return on Cardiol Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.7M | |
| Net Loss Per Executive | 4.7M | |
| Working Capital Per Employee | 8.6M | |
| Working Capital Per Executive | 8.6M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Cardiol Stock analysis
When running Cardiol Therapeutics' price analysis, check to measure Cardiol Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiol Therapeutics is operating at the current time. Most of Cardiol Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cardiol Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiol Therapeutics' price. Additionally, you may evaluate how the addition of Cardiol Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |